Lincoln Pharmaceuticals has announced a board meeting to discuss the financial results for the quarter and half-year.

Their new manufacturing facility in Gujarat has completed trial runs, aiming to start commercial API production within 1-2 years, subject to product approvals.

The planned capacity addition is 1.2 tonnes per annum, backed by an INR 4 Cr investment funded through internal accruals.

This expansion targets increased market demand and supports internal consumption.